Skip to content Skip to footer
Subscribe Now

NEWS

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis
Shots: The P-III (ASCEND) trial evaluated rocatinlimab (150 or 300mg, Q4W/Q8W) in ~2,600 atopic dermatitis pts who completed 24wks. in ROCKET trial program & continued for 32wks. in ASCEND, which will evaluate long-term safety & efficacy up to 104wks. Trial showed a favorable long-term safety profile (1EP) with low discontinuation rates due to AEs, consistent…
September 9, 2025
Novartis to Acquire Tourmaline Bio for ~$1.4B, Complementing its Cardiovascular Portfolio
Shots: Novartis has entered into an agreement to acquire Tourmaline Bio, incl. its asset pacibekitug, expanding its cardiovascular portfolio As per the deal, Novartis, through its subsidiary, will acquire Tourmaline for $48/share, representing an aggregate of ~$1.4B, & will merge the subsidiary into Tourmaline upon completion, making it an indirect wholly owned unit of Novartis; closing…
September 9, 2025
Eli lilly
Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shots: Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD) vs chemoimmunotherapy (bendamustine + rituximab) in 282 pts with 1L chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions Trial met its 1EP of improved PFS per IRC, while OS was immature but showed a favorable trend &…
September 8, 2025
Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M
Shots: Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS) As per the deal, Kaerus will receive a total of ~$450M incl. an upfront payment as well as development & commercial milestones KER-0193 is a BK channel modulator, which showed improvement across syndrome-relevant…
September 8, 2025
Hengrui Pharma Enters a ~$1.08B Deal with Braveheart Bio for HRS-1893
Shots: Hengrui Pharma & Braveheart Bio have entered into an exclusive license agreement for Hengrui’s HRS-1893 to treat cardiovascular diseases As per the deal, Braveheart will obtain exclusive global rights (ex-China, Hong Kong, Macao & Taiwan) to develop, manufacture & commercialize HRS-1893 in exchange for $65M upfront (50% in cash + 50% in shares), ~$10M…
September 8, 2025
SignalPET Launches SignalPET 360° for Comprehensive Veterinary Radiology
Shots: SignalPET has launched SignalPET 360°, an integrated AI-powered radiology solution for veterinary medicine SignalPET 360 provides an integrated diagnostic platform with built-in PACS, allowing clinics to store & view all imaging modalities, generate AI-powered reports for every case, & seamlessly escalate to advanced AI or radiologist review when required SignalPET 360° suite provides immediate…
September 5, 2025
Load more